[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"volume-overload\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:volume-overload":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,47,85,110,133],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100600379","boston-medical-center-ultrasound-decongestion-study-in-heart-failure-100600379",false,"NCT07096726","Boston Medical Center Ultrasound Decongestion Study in Heart Failure","Boston Medical Center Ultrasound Decongestion Study","BUDS-HF","Inclusion Criteria:\n\n* Patient with a primary diagnosis of acute on chronic decompensated heart failure who is admitted to inpatient or presents to the outpatient Boston Medical Center (BMC) Heart Failure Infusion clinic for decongestion treatment.\n* Willing and able to receive short abdominal and thoracic ultrasounds throughout hospitalization\n* Patients with right and\u002For left ventricular failure\n\nExclusion Criteria:\n\n* Hemodynamic instability defined as systolic blood pressure \\\u003C85 mmHg or mean arterial pressure \\\u003C60 mm Hg for greater than 24 hours duration\n* Abdominal surgery in the past 1 month\n* Significant acute or chronic liver disease\n* End stage renal disease on dialysis\n* Advanced chronic kidney disease (CKD) \\[Stage V CKD with glomerular filtration rate (GFR) \\\u003C15\\] to exclude renal vein doppler ultrasound\n* Severe acute kidney injury (AKI) or requiring renal replacement therapy\n* Known abdominal thrombus in the inferior vena cava (IVC) or portal vein\n* Acute myocarditis\n* Acute valvular disease\n* Acute type 1 myocardial infarction\n* Medical condition precluding abdominal ultrasound due to significant discomfort or pain\n* Adults not able to provide consent (a simple teach back method of key aspects discussed in consent form will be utilized to verify if patient is able to adequately provide informed consent)","ALL","18 Years",{"count":20,"type":21},200,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of this study is to analyze the utility of a novel five-point ultrasound as a predictor of volume overload in diverse patients who are admitted with volume overload\u002Fcongestive heart failure (CHF) exacerbation at Boston Medical Center (BMC), the largest safety-net hospital in New England. Current standard of care (SOC) involves the utilization of laboratory markers and physical exam, which is often inconsistent and equivocal. The investigators will assess will assess if ultrasound-assisted diuresis reduces recurrent episodes of volume overload\u002Fdecompensated heart failure.",[27,28],"Congestive Heart Failure","Volume Overload",[30,31,32,33],"Venous Excess Ultrasound (VExUS)","Ultrasound-assisted diuresis","Heart Failure with Preserved Ejection Fraction (HFpEF)","Heart Failure with Reduced Ejection Fraction (HFrEF)","NOT_YET_RECRUITING","2026-06-29",{"date":37,"type":38},"2026-06-30","ACTUAL",{"date":40,"type":21},"2026-09",{"date":42,"type":21},"2027-12",{"name":44,"class":45},"Boston Medical Center","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":65,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":84},"100644867","euvolemia-based-assessment-of-pulmonary-hypertension-in-stable-hemodialysis-patients-100644867","NCT07676786","Euvolemia-Based Assessment of Pulmonary Hypertension in Stable Hemodialysis Patients","Prospective Observational Study on Predictors and Types of Pulmonary Hypertension in Euvolemic Patients With End-Stage Kidney Disease on Maintenance Hemodialysis","EU-PHASE-HD","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* End-stage kidney disease on maintenance HD for ≥ 3 months.\n* Stable clinical condition (no hospitalization in last 30 days).\n* Able and willing to comply with study protocol.\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Moderate\u002Fsevere left-sided valvular disease.\n* Active pulmonary or cardiac decompensation.\n* Persistent hypervolemia after completion of the volume assessment and correction phase\n* Inability to undergo echocardiography or bioimpedance assessment.\n* Acute infection or inflammatory condition at the time of enrollment.\n* Inadequate echocardiographic window preventing reliable assessment",{"count":56,"type":21},30,"OBSERVATIONAL","Pulmonary hypertension (PH) is a frequent and clinically significant complication in patients with end-stage kidney disease (ESKD) undergoing maintenance hemodialysis (HD). However, PH assessment in this population is often confounded by volume overload, leading to potential overestimation and misclassification.\n\nThis prospective, multicenter observational study aims to evaluate the prevalence, phenotype, and predictors of PH in HD patients under standardized euvolemic conditions. A structured pretrial phase including volume assessment and correction will be performed prior to echocardiographic evaluation, which will be conducted after confirmation of euvolemia, post-hemodialysis or on the following day.\n\nIn participants with echocardiographic findings suggestive of PH, right heart catheterization may be performed when clinically indicated and after obtaining specific informed consent.\n\nThe study integrates clinical, biological, dialysis-related, and echocardiographic data to provide a comprehensive characterization of PH in a well-defined ESKD population.",[60,61,62,28,63,64],"Pulmonary Hypertension (PH)","End Stage Kidney Disease (ESRD)","Hemodialysis Patients","Volume Assessment","Hemodialysis",[66,64,67,68,28,69,70,71,72,73,74,75],"Pulmonary Hypertension","End-Stage Kidney Disease","Euvolemia","Volume Status","Echocardiography","Bioimpedance Spectroscopy","Interdialytic Weight Gain","Vascular Access","Blood Pressure Variability","Lung Ultrasound","2026-06-24",{"date":37,"type":38},{"date":79,"type":21},"2026-07-01",{"date":81,"type":21},"2027-03-30",{"name":83,"class":45},"Stefan Lujinschi",2,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":22,"phases":95,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":46},"100591384","phase-4-gator-scales-whf-subcutaneous-administration-of-lasix-to-eliminate-symptoms-of-worsening-heart-failure-100591384","NCT06979726","Gator SCALES-WHF: SubCutaneous Administration of Lasix to Eliminate Symptoms of Worsening Heart Failure","GatorScalesWHF","Inclusion Criteria:\n\n1. Age 18 or above\n2. Previously diagnosed with Congestive Heart Failure (HFpEF or HFrEF)\n3. Fluid overload due to worsening HF requiring parenteral diuretic treatment as assessed by at least 2 of the following:\n\n   1. BNP \\> 200\n   2. JVP \\> 10cmH20\n   3. Presence of S3\n   4. LE Edema\n   5. Weight gain of \\> 5lbs in the past 5 days\n4. Failed oral uptitration of loop diuretic over the prior 5 days or presented with symptoms too advance to justify additional oral uptitration attempts to resolve congestion symptoms.\n5. Expected to require a minimum of three days of parenteral diuretic treatment\n6. Written informed consent\n7. Able and willing to operate Lasix ONYU and comply with study requirements or has a caregiver who can assume these roles.\n\nExclusion Criteria:\n\n1. Age above 80 years\n2. Unable or unwilling to provide informed consent.\n3. Any medical condition or circumstances that would require further clinical investigation or hospitalization\n4. Presence or history of electrolyte abnormalities that may be exacerbated by parenteral loop diuretic treatment\n5. Home or current living environment not suitable for outpatient management and diuresis\n6. Pregnant or breastfeeding\n7. Unable to comply with clinic-required follow up procedure\n8. Baseline chronic renal disease with CKD Stage V\n9. Any surgical or medical condition which, in the opinion of the investigator, may pose an undue risk to the subject, interfere with participation in the study or which may affect the integrity of the data","80 Years",{"count":94,"type":21},100,[96],"PHASE4","The primary objective of the study is to develop, implement, and evaluate a site-specific clinical pathway for at-home treatment of eligible patients presenting to the clinic with worsening heart failure.\n\nThe secondary objectives are:\n\n1. To evaluate patient factors related to parenteral decongestion at home.\n2. To evaluate the safety and device operation of Lasix ONYU treatment under circumstances that mimic real-world use.\n3. To identify opportunities for process improvement before the routine implementation of the new clinical pathway.",[99,28],"Heart Failure","RECRUITING","2026-06-03",{"date":103,"type":38},"2026-06-08",{"date":105,"type":38},"2025-11-20",{"date":107,"type":21},"2026-12-31",{"name":109,"class":45},"University of Florida",{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":22,"phases":120,"briefSummary":121,"conditions":122,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":4},"100640947","phase-4-infusion-of-furosemide-to-improve-diuretic-efficiency-in-acute-heart-failure-100640947","NCT07577596","Infusion of Furosemide to Improve Diuretic Efficiency in Acute Heart Failure","Infusion of Furosemide to Improve Diuretic Efficiency in Acute Heart Failure (INFUSE-AHF)","INFUSE-AHF","Inclusion Criteria:\n\n* Clinical diagnosis of acute heart failure with volume overload\n* At least 1 sign of volume overload\n* Anticipated intravenous furosemide treatment for at least 3 days\n* Age 18 years or older\n\nExclusion Criteria:\n\n* Shock\n* Patient requiring treatment with inotropes or vasopressors\n* Current or planned use of renal replacement therapy or ultrafiltration\n* Patient with a renal transplant\n* Patients who are pregnant or breastfeeding\n* Severe hypokalaemia, defined as potassium less than 2.5 mmol\u002FL, or severe hyponatremia, defined as sodium less than 125 mmol\u002FL\n* Allergy to furosemide and its components",{"count":119,"type":21},436,[96],"Acute heart failure is a condition where the heart suddenly cannot pump blood well enough for the body's needs. Many people admitted to the hospital with acute heart failure have too much fluid in the body. This can cause shortness of breath, swelling, and the need for treatment with water-removing medicine.\n\nFurosemide is a commonly used water-removing medicine that is given into a vein to treat fluid overload. It can be given in different ways. One way is as a continuous infusion, where the medicine is given slowly over time through a pump. Another way is as repeated injections given several times a day. It is not known whether one of these ways is better than the other for removing excess fluid in people with acute heart failure.\n\nThe purpose of this study is to compare two ways of giving furosemide into a vein: Continuous infusion started with an initial extra dose, and bolus injections given three times a day. About 436 adults admitted to hospitals in Denmark with acute heart failure and fluid overload will take part. Participants will be randomly assigned to one of the two treatment groups. This means that chance will decide which treatment method each participant receives.\n\nThe main thing the researchers will measure is how much body weight participants lose about 3 days after randomization. Weight loss is used as a measure of how much excess fluid has been removed.",[123,28],"Acute Heart Failure","2026-05-05",{"date":126,"type":38},"2026-05-11",{"date":128,"type":21},"2026-05-01",{"date":130,"type":21},"2027-10-01",{"name":132,"class":45},"University of Aarhus",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":139,"enrollmentInfo":140,"targetDuration":4,"studyType":22,"phases":142,"briefSummary":143,"conditions":144,"keywords":147,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":46},"100547959","phase-4-efficacy-and-safety-of-combination-diuretic-therapy-in-patients-with-acute-decompensated-heart-failure-and-volume-overload-100547959","NCT06414759","Efficacy and Safety of Combination Diuretic Therapy in Patients With Acute Decompensated Heart Failure and Volume Overload","Inclusion Criteria:\n\n* Male or female patients with ages ≥ 18 years old, and less than 65 years old.\n* For both elective and emergency hospital admissions, patients with a clinical diagnosis of ADHF must exhibit at least one clinical sign indicative of volume overload. These signs may include edema (score 2 or higher), ascites confirmed through echography, or pleural effusion confirmed by chest X-ray or echography or rales on auscultation, or jugular venous pressure greater than10 mm Hg.\n\nExclusion Criteria:\n\n* Patient diagnosed with acute kidney injury upon hospital admission based on the presence of any of the following criteria: an increase in SCr by at least 0.3 mg\u002FdL within 48 hours, an increase in SCr to at least 2 times the baseline value, known or presumed to have occurred within the prior 7 days, and a urine volume less than 0.5 ml\u002Fkg\u002Fhour for a duration of 6 hours.\n* Patients with acute pulmonary edema caused by increased afterload and fluid redistribution to the lungs in the absence or with minimal fluid accumulation.\n* Anticipated exposure to nephrotoxic agents (such as contrast dye) during hospitalization.\n* Patients who exhibit anuria or are undergoing renal replacement therapy or ultrafiltration.\n* Patients with eGFR less than 30 mL\u002Fmin\u002F1.73m² at the time of screening.\n* Expected use of intravenous inotropes, vasopressors, or nitroprusside during the study.\n* Prior cardiac transplantation and\u002For utilization of a ventricular assist device.\n* Blood pressure below 90 mmHg or mean arterial pressure below 65 mmHg at the time of recruitment.\n* Patients who are pregnant or breastfeeding.\n* Administration of acetazolamide or metolazone within the one-month period preceding randomization.\n* The usage of any diuretic agent during the treatment phase is not specified in the study protocol, except for mineralocorticoid receptor antagonists.","65 Years",{"count":141,"type":21},110,[96],"This study aims to compare two medications, acetazolamide and metolazone, along with loop diuretics, to see which one works better and is safer for patients with ADHF who have volume overload. By comparing these medications, we hope to learn which one can help these patients the most. This will help doctors choose the best treatment for patients with ADHF and volume overload.",[145,28,146],"Acute Decompensated Heart Failure","Edema",[148,145,149,123,150,146,151,152,153,154,155,156,157],"ADHF","AHF","Volume overload","Loop diuretics","Fusrosemide","Metolazone","Acetazolamide","Carbonic anhydrase inhibitor","Thiazide like diuretics","Thiazide diuretics","2024-07-23",{"date":160,"type":38},"2024-07-24",{"date":162,"type":38},"2024-07-01",{"date":164,"type":21},"2025-03-30",{"name":166,"class":45},"Cairo University"]